Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Peter Diamandis

Andrew L. Pecora

Robert J. Hariri

Celularity Inc.

GC Therapeutics harnesses an induced pluripotent stem cell (iPSC) cellular programming platform to improve patient access across various therapeutic areas, focusing on gastrointestinal, neurological, and immunological diseases.

GC Therapeutics

Jaguar Gene Therapy focuses on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, according to their self-described mission.

Jaguar Gene Therapy

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com.

Dragasac Limited

Sorrento Therapeutics

Starr Insurance Companies

Alumni Ventures

Heritage Group

Human Longevity

Section 32 Celgene

United Therapeutics

Bill Maris

Tony Robbins

We're excited for the future here at Celularity and are off to an invigorating 2024! Net sales expectations and updates can be found in the full release, linked below.

Exciting announcement! The opportunity to manufacture placental-derived biomaterials for distribution by BioCellgraft will bring our exceptional, proven technology to the management of oral healthcare concerns and fill the treatment gap for patients who suffer from soft tissue and hard tissue conditions.

Excited about the future at Celularity!
https://lnkd.in/gmJmRJCP

We're pleased to have had our Chairman, CEO and Founder, Dr. Bob Hariri, featured by Cell & Gene .  Discussion topics included lessons learned in allogeneic cell therapy, advice for allogeneic cell therapy start-ups, the strategy behind the Celularity facility, and more. 
#celltherapy #cellandgenetherapy 
https://lnkd.in/dj2Sr_3c

We’re pleased to announce our exclusive U.S. commercialization agreement with Verséa Health (Verséa Ophthalmics), which will allow us to support eye care professionals as they treat ocular surface diseases and perform certain ocular surgeries. Discover more about the partnership: https://bit.ly/3YcZdOM

Next Wednesday, July 26, our team will present data on Celularity’s proprietary #biomaterials at the International Conference on Biomaterials Science and Tissue Engineering (ICBSTE) in Osaka, Japan.

Presented by Anna Gosiewska, PhD, the data will include three benchtop and clinical case studies for three Celularity human placental-derived advanced biomaterial products. Find out more about the data here: https://bit.ly/3JY4LXS

Check out this interview with our Chairman, CEO and Founder, Dr. Bob Hariri, in the latest issue of Pulse 2.0
https://lnkd.in/ejr2bu6X

Next month, Celularity will present at the 7th International Conference on Orthopedics in Rome. The oral session will share data from a new technology in development for orthopedic applications.
 
Read the full announcement to learn more about the study: https://bit.ly/3NpgMGA

Exciting update: data featured in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor (TF) gene knock out (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower TF expression, activity, and thrombotic effects. This #preclinical #data from an edited version of one of our cell therapy candidates signals a feasible pathway to potentially improve the safety of ASC-based #celltherapy.
 
Full details here: https://bit.ly/3qjvHua

Today, we are excited to announce that we have received a $45 million purchase order for Celularity private label Halal-Certified #biomaterial products from Jamjoom Medicine Store.
 
This marks the first purchase order received under our recently announced expansion into the Middle East market, as part of our global market strategy. Read the full announcement: https://bit.ly/426nqXw

Metric
Company Name	Celularity Inc.	GC Therapeutics	Jaguar Gene Therapy
Symbol	CELU
MSH ID	COM:CELULARITY	COM:GC-TX	COM:JAGUARGENETHERAPY
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage		Series A	Venture Round
Employee Count	225
Website	celularity.com	gc-tx.com	jaguargenetherapy.com
LinkedIn	celularity
Founders

Metric
Market Cap	61.43M
Enterprise Value
Monthly Web Traffic		1.68K	1
Web Traffic Growth		-0.43	-1.00
Valuation
Raised Capital		65M

Metric
Revenue	22.77M
Revenue (LTM)
Revenue (NTM)
Gross Profit	6.75M
EBITDA	-74.30M
Operating Income	-192.29M
Net Income	-196.29M
EPS	-11.02
Diluted EPS	-11.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.57
Operating Profit Margin	-4.05
EBITDA Margin	-3.26
Net Profit Margin	-4.60
Return on Equity	-1.44
Return on Assets	-0.92
Return on Capital Employed	-1.68

COM:CELULARITY

Celularity Inc.

Last Close

2.85

22/11 21:00

Market Cap

61.43M

Beta: -

Volume Today

104.87K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.49
P/B Ratio	2.93
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.73
EV Multiple	0.56

Metric
Days Sales Outstanding	152.68
Days Payables Outstanding	132.68
Days Inventory Outstanding	147.30
Operating Cycle	382.12
Cash Conversion Cycle	117.55
Asset Turnover	0.23

Metric
Operating Cash Flow	-38.69M
Free Cash Flow	-42.73M
Cash Flow to Debt	-0.36
Operating Cash Flow/Sales	-0.84
Free Cash Flow Yield	-0.67

Metric
Cash & Equivalents	227K
Accounts Receivable	-6.83M
Inventory	5.75M
Goodwill	7.35M
Debt to Capitalization	0.68
Debt to Assets	0.39
Current Ratio	0.19
Quick Ratio	0.29

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.07
R&D to Revenue	2.82
SG&A to Revenue